Gene therapy with mesenchymal stem cells expressing IFN-ß ameliorates neuroinflammation in experimental models of multiple sclerosis
详细信息 查看全文
- 作者：C Marin-Bañ ; asco ; K Benabdellah ; C Melero-Jerez ; B Oliver ; M J Pinto-Medel ; I Hurtado-Guerrero ; F de Castro ; D Clemente ; O Ferná ; ndez ; F Martin ; L Leyva and M Suardí ; az
- 刊名：British Journal of Pharmacology
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：174
- 期：3
- 页码：238-253
- 全文大小：859K
- ISSN：1476-5381
文摘
Recombinant IFN-ß is one of the first-line treatments in multiple sclerosis (MS), despite its lack of efficacy in some patients. In this context, mesenchymal stem cells (MSCs) represent a promising therapeutic alternative due to their immunomodulatory properties and multipotency. Moreover, by taking advantage of their pathotropism, these cells can be genetically modified to be used as carriers for delivering or secreting therapeutic drugs into injured tissues. Here, we report the therapeutic effect of systemic delivery of adipose-derived MSCs (AdMSCs), transduced with the IFN-β gene, into mice with experimental autoimmune encephalomyelitis (EAE).